Convalescent Plasma to Treat COVID-19: A Two-Center, Randomized, Double-Blind Clinical Trial

被引：4

作者：

Ventura-Enriquez, Yanet ^{[1
]}

Cabello-Gutierrez, Carlos ^{[2
]}

Augusto Perez-Calatayud, Angel ^{[3
]}

Cortina-De la Rosa, Evelyn ^{[1
,4
]}

Javier Fareli-Gonzalez, Christian ^{[5
]}

Castillo-Juarez, Paola ^{[2
,6
]}

Pena-Perez Carlos, Alberto ^{[7
]}

Omar Zavaleta-Martinez, Eli ^{[7
]}

Diaz-Padilla, Elizabeth ^{[1
,8
]}

Murrieta, Sandra ^{[1
]}

Deyanira Alvarez-Jimenez, Violeta ^{[9
]}

Diaz Ponce-Medrano, Juan Alberto ^{[10
]}

Casillas-Suarez, Catalina ^{[3
]}

Angelica Ocampo-Ocampo, Maria ^{[3
]}

Vargas-De-Leon, Cruz ^{[11
,12
]}

Fernandez-Sanchez, Veronica ^{[1
,11
,13
]}

机构：

[1] Ctr Med Naval CEMENAV, Banco Sangre, Ciudad De Mexico 04470, Mexico

[2] Inst Nacl Enfermedades Resp INER, Dept Invest Virol & Micol, Ciudad De Mexico 14080, Mexico

[3] Hosp Gen Mexico Dr Eduardo Liceaga, Div Med Crit, Ciudad De Mexico 06720, Mexico

[4] Inst Nacl Cardiol Ignacio Chavez, Dept Hematol, Ciudad De Mexico 14080, Mexico

[5] Natl Ctr Technol Excellence Hlth, Guias Pract Clin, Ciudad De Mexico 06600, Mexico

[6] Inst Politecn Nacl IPN, Dept Microbiol, Escuela Nacl Ciencias Biol, Ciudad De Mexico 11340, Mexico

[7] Ctr Med Naval CEMENAV, Unidad Cuidados Intensivos, Ciudad De Mexico 04470, Mexico

[8] UNAM, Fac Quim, Ciudad De Mexico 04510, Mexico

[9] Ctr Med Naval CEMENAV, Biol Mol & BSL 3, Ciudad De Mexico 04470, Mexico

[10] Ctr Med Naval CEMENAV, Direcc Gen, Ciudad De Mexico 04470, Mexico

[11] Hosp Juarez Mexico, Div Invest, Ciudad De Mexico 07760, Mexico

[12] Inst Politecn Nacl IPN, Escuela Super Med, Secc Estudios Invest & Posgrad, Ciudad De Mexico 11340, Mexico

[13] Univ Nacl Autonoma Mexico, Fac Estudios Super Iztacala FES Iztacala, Ciudad De Mexico 54090, Mexico

来源：

LIFE-BASEL | 2022年 / 12卷 / 11期

关键词：

convalescent plasma treatment; COVID-19; neutralizing antibodies; SARS-CoV-2; MORTALITY;

D O I：

10.3390/life12111767

中图分类号：

Q [生物科学];

学科分类号：

07 ; 0710 ; 09 ;

摘要：

Background: The use of convalescent plasma (CP) has been considered for its immunological mechanisms that could benefit patients in moderate and severe stages of COVID-19. This study evaluated the safety and efficacy of the use of donor CP for COVID-19. Material and methods: A double-blind, randomized controlled clinical trial was conducted from May to October 2020. Thirty-nine participants with moderate (II) and severe (III) stages of COVID-19 confirmed by RT-PCR were included. The study randomization rate was set at 3:1. CPs were chosen for application with a neutralizing antibody titer of >= 1:32. Results: We observed a significantly lower 21-day post-transfusion mortality HR: 0.17 (95.0% CI [0.07-0.45, p < 0.001]) in the group receiving CP compared with the control group; protective units (PU) in the group receiving convalescent plasma after seven days were significantly higher (512 (32-16,384) vs. 96 (32-256), p = 0.01); the PAO(2)/FIO2 index showed a significant improvement in the group receiving CP (251.01 (109.4) vs. 109.2 (62.4), p < 0.001, in the control group). Conclusion: CP is safe and effective, as it decreased mortality in the CP group compared with the control group.

引用

页数：13

共 50 条

[1] A randomized double-blind controlled trial of convalescent plasma in adults with severe COVID-19
O'Donnell, Max R.
Grinsztejn, Beatriz
Cummings, Matthew J.
Justman, Jessica E.
Lamb, Matthew R.
Eckhardt, Christina M.
Philip, Neena M.
Cheung, Ying Kuen
Gupta, Vinay
Joao, Esau
Pilotto, Jose Henrique
Diniz, Maria Pia
Cardoso, Sandra Wagner
Abrams, Darryl
Rajagopalan, Kartik N.
Borden, Sarah E.
Wolf, Allison
Sidi, Leon Claude
Vizzoni, Alexandre
Veloso, Valdilea G.
Bitan, Zachary C.
Scotto, Dawn E.
Meyer, Benjamin J.
Jacobson, Samuel D.
Kantor, Alex
Mishra, Nischay
Chauhan, Lokendra, V
Stone, Elizabeth F.
Dei Zotti, Flavia
La Carpia, Francesca
Hudson, Krystalyn E.
Ferrara, Stephen A.
Schwartz, Joseph
Stotler, Brie A.
Lin, Wen-Hsuan W.
Wontakal, Sandeep N.
Shaz, Beth
Briese, Thomas
Hod, Eldad A.
Spitalnik, Steven L.
Eisenberger, Andrew
Lipkin, Walter, I
[J]. JOURNAL OF CLINICAL INVESTIGATION, 2021, 131 (13):
[2] Convalescent plasma to treat COVID-19
Bloch, Evan M.
[J]. BLOOD, 2020, 136 (06) : 654 - 655
[3] Topiramate Combined with Cognitive Restructuring for the Treatment of Gambling Disorder: A Two-Center, Randomized, Double-Blind Clinical Trial
Cabrita de Brito, Antonio Marcelo
de Almeida Pinto, Moema Galindo
Bronstein, Gabriel
Carneiro, Elizabeth
Faertes, Daniela
Fukugawa, Viviane
Duque, Angela
Vasconcellos, Fatima
Tavares, Hermano
[J]. JOURNAL OF GAMBLING STUDIES, 2017, 33 (01) : 249 - 263
[4] Topiramate Combined with Cognitive Restructuring for the Treatment of Gambling Disorder: A Two-Center, Randomized, Double-Blind Clinical Trial
Antonio Marcelo Cabrita de Brito
Moema Galindo de Almeida Pinto
Gabriel Bronstein
Elizabeth Carneiro
Daniela Faertes
Viviane Fukugawa
Angela Duque
Fatima Vasconcellos
Hermano Tavares
[J]. Journal of Gambling Studies, 2017, 33 : 249 - 263
[5] Convalescent plasma to treat COVID-19: clinical experience and efficacy
Pei, Shiyao
Yuan, Xi
Zhang, Zhimin
Yao, Run
Xie, Yubin
Shen, Minxue
Li, Bijuan
Chen, Xiang
Yin, Mingzhu
[J]. AGING-US, 2021, 13 (06): : 7758 - 7766
[6] Reinforcement of the Standard Therapy with Two Infusions of Convalescent Plasma for Patients with COVID-19: A Randomized Clinical Trial
Bargay-Lleonart, Joan
Sarubbo, Fiorella
Arrizabalaga, Maria
Guerra, Jose Maria
Borras, Josep
El Haji, Khaoulah
Flexas, Magdalena
Perales, Jorge
Fernandez-Baca, Victoria
Gallegos, Carmen
Cruz, Manuel Raya
Velasco, Sonia
Lopez, Victor
Cruz, Ana
Bautista-Gili, Antonia
Jimenez-Marco, Teresa
Girona-Llobera, Enric
Vilaplana, Laia
Calonge, Laura
Tena, Juan
Galan, Maria Pilar
Payeras, Antoni
[J]. JOURNAL OF CLINICAL MEDICINE, 2022, 11 (11)
[7] Hydrogen peroxide as an auxiliary treatment for COVID-19 in Brazil: a randomized double-blind clinical trial
Di Domenico, Marielle Bazzo
Collares, Kaue
Dos Santos, Renan Brandenburg
Lenz, Ulysses
Antunes, Vinicius Picoli
Godinho, Vinicius Webber
Cesca, Henrique
Jincziwski Ponciano, Thales Henrique
Corazza, Pedro Henrique
[J]. EPIDEMIOLOGY AND HEALTH, 2021, 43
[8] Effects of Ivermectin in Patients With COVID-19: A Multicenter, Double-blind, Randomized, Controlled Clinical Trial
Shahbaznejad, Leila
Davoudi, Alireza
Eslami, Gohar
Markowitz, John S.
Navaeifar, Mohammad Reza
Hosseinzadeh, Fatemeh
Movahedi, Faeze Sadat
Rezai, Mohammad Sadegh
[J]. CLINICAL THERAPEUTICS, 2021, 43 (06) : 1007 - 1019
[9] A Randomized Trial of Convalescent Plasma in Covid-19 Severe Pneumonia
Simonovich, V. A.
Pratx, L. D. Burgos
Sabana, P.
Beruto, M., V
Vallone, M. G.
Vazquez, C.
Savoy, N.
Giunta, D. H.
Perez, L. G.
Sanchez, M. L.
Gamarnik, A., V
Ojeda, D. S.
Santoro, D. M.
Camino, P. J.
Antelo, S.
Rainero, K.
Vidiella, G. P.
Miyazaki, E. A.
Cornistein, W.
Trabadelo, O. A.
Ross, F. M.
Spotti, M.
Funtowicz, G.
Scordo, W. E.
Losso, M. H.
Ferniot, I
Pardo, P. E.
Rodriguez, E.
Rucci, P.
Pasquali, J.
Fuentes, N. A.
Esperatti, M.
Speroni, G. A.
Nannini, E. C.
Matteaccio, A.
Michelangelo, H. G.
Follmann, D.
Lane, H. C.
Belloso, W. H.
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2021, 384 (07): : 619 - 629
[10] Convalescent plasma to treat coronavirus disease 2019 (COVID-19): considerations for clinical trial design
Barone, Paul
DeSimone, Robert A.
[J]. TRANSFUSION, 2020, 60 (06) : 1123 - 1127

← 1 2 3 4 5 →